OncoMatch/Clinical Trials/NCT06588478
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Is NCT06588478 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pirtobrutinib for chronic lymphocytic leukemia.
Treatment: Pirtobrutinib — The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Chronic Lymphocytic Leukemia
Biomarker criteria
Required: TP53 17p deletion
Part 2 - Must have 17p deletion (positive)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: BTK inhibitor
Have received a covalent BTK inhibitor
Cannot have received: BTK degrader
Have received prior treatment with a BTK degrader
Cannot have received: noncovalent BTK inhibitor
Have received prior treatment with a ... noncovalent BTK inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ironwood Cancer & Research Centers · Chandler, Arizona
- City of Hope National Medical Center · Duarte, California
- City of Hope National Medical Center · Irvine, California
- Palo Alto Medical Foundation Research Institute (PAMFRI) · Palo Alto, California
- Stanford Cancer Center · Palo Alto, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06588478 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BTK degrader, noncovalent BTK inhibitor disqualifies patients from enrollment.
Does this trial require TP53?
Yes, TP53 17p deletion is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify